Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/697,546	WYNN ET AL.	
Examiner	Art Unit	

N	IICAH-PAUL YOUNG	1618	
The MAILING DATE of this communication appear	s on the cover sheet with the	correspondence add	ress
THE REPLY FILED <u>24 October 2008</u> FAILS TO PLACE THIS AP	PLICATION IN CONDITION FO	R ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or on th application, applicant must timely file one of the following repapplication in condition for allowance; (2) a Notice of Appeal for Continued Examination (RCE) in compliance with 37 CFI periods:	e same day as filing a Notice of plies: (1) an amendment, affidav (with appeal fee) in compliance	Appeal. To avoid abar it, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
 a) The period for reply expiresmonths from the mailing day b) The period for reply expires on: (1) the mailing date of this Advince event, however, will the statutory period for reply expire late Examiner Note: If box 1 is checked, check either box (a) or (b). 	sory Action, or (2) the date set forth r than SIX MONTHS from the mailin	g date of the final rejectio	n.
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on have been filed is the date for purposes of determining the period of exten under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the sho set forth in (b) above, if checked. Any reply received by the Office later the may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	which the petition under 37 CFR 1.7 sion and the corresponding amount rtened statutory period for reply orig	36(a) and the appropriate of the fee. The appropriationally set in the final Offic	e extension fee ate extension fee e action; or (2) as
 The Notice of Appeal was filed on A brief in complia filing the Notice of Appeal (37 CFR 41.37(a)), or any extensi Notice of Appeal has been filed, any reply must be filed with AMENDMENTS 	on thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
3. The proposed amendment(s) filed after a final rejection, but (a) They raise new issues that would require further consi (b) They raise the issue of new matter (see NOTE below) (c) They are not deemed to place the application in better	deration and/or search (see NO ;	TE below);	
appeal; and/or (d) They present additional claims without canceling a cor NOTE: (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121.	See attached Notice of Non-Co		PTOL-324).
 5. Applicant's reply has overcome the following rejection(s): _ 6. Newly proposed or amended claim(s) would be allow non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a) 	vable if submitted in a separate,		
how the new or amended claims would be rejected is provided the status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 13-16,18-22,25-27,29-31,34 and 36-46. Claim(s) withdrawn from consideration:		ii be entereu anu an e <i>i</i>	кріанацон о
 AFFIDAVIT OR OTHER EVIDENCE The affidavit or other evidence filed after a final action, but b because applicant failed to provide a showing of good and s was not earlier presented. See 37 CFR 1.116(e). 			
9. The affidavit or other evidence filed after the date of filing a lentered because the affidavit or other evidence failed to ove showing a good and sufficient reasons why it is necessary a	rcome <u>all</u> rejections under appe nd was not earlier presented. S	al and/or appellant fails ee 37 CFR 41.33(d)(1)	s to provide a).
 The affidavit or other evidence is entered. An explanation of REQUEST FOR RECONSIDERATION/OTHER The request for reconsideration has been considered because: See Continuation Sheet. 		•	
12. ☐ Note the attached Information <i>Disclosure Statement</i>(s). (PT13. ☐ Other:	ΓΟ/SB/08) Paper No(s)		
/Michael G. Hartley/ Supervisory Patent Examiner, Art Unit 1618	/MICAH-PAUL YOUNG Examiner, Art Unit 1618		

Application No.

Continuation of 11. does NOT place the application in condition for allowance because: The prior art discloses a dosage from comprising an immediate release portion and a second controlled release portion of granules comprising NSAID drugs. The dosage from can be suspended in water to form a liquid suspension. The coating of the granules is identical that of the instant claims. Table 2 shows the combination of enteric polymers with film forming polymers. These film forming polymers can be either water soluble or water insoluble as described at col. 4, lin. 39-68. Applicant argues that the prior art does not disclose both enteric and water insoluble polymers, but as can be seen the water insoluble polymers can clearly be substituted and combined with the enteric polymer for use as a coating material. For these reasons the claims remain rejected.